Avi Biopharma Inc - Current report filing (8-K)
March 12 2008 - 2:53PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported):
March 10, 2008
AVI BioPharma, Inc.
(Exact name of Company as specified in its
charter)
Oregon
|
|
001-14895
|
|
93-0797222
|
(State or other
|
|
(Commission File No.)
|
|
(I.R.S. Employer
|
jurisdiction of
|
|
|
|
Identification No.)
|
incorporation)
|
|
|
|
|
One S.W.
Columbia, Suite 1105
Portland,
OR 97258
(Address of principal executive offices)
(503)
227-0554
Registrants telephone number, including area
code
Not
Applicable
(Former name or former address, if changed
since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item 2.02
Results of Operation and
Financial Condition
.
On March 12, 2008, AVI BioPharma Inc. (the
Company) issued a press release announcing, among other items, its financial
results for the fourth quarter ended December 31, 2007 and for the
full-year 2007. A copy of the Companys press release dated March 12, 2008
is attached as Exhibit 99.1 to this Form 8-K
and is incorporated herein
by reference.
Item 5.02 Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers
On March 10, 2008, Jack L. Bowman announced his
resignation as a director and Chairman of the Board of Directors of the Company,
which also included a resignation from all committees on which he was a member,
effective immediately. Mr. Bowmans
resignation was for personal reasons, and was not the result of any
disagreement with the Company on any matter relating to the Companys
operations, policies, or practices. In
connection with Mr. Bowmans resignation as a director, the Board of
Directors of the Company appointed Michael D. Casey, an existing member of the
Board of Directors, as the Chairman of the Board of Directors and approved a
decrease in the number of directors from eight (8) to seven (7), effective
immediately.
On March 12, 2008, the Company issued a press
release announcing the foregoing changes. A copy of the Companys press release
dated March 12, 2008 is attached as Exhibit 99.1 to this Form 8-K
and is incorporated herein by reference.
Item 7.01 Regulation
FD Disclosure
The information set forth above is incorporated by
reference herein.
Item 8.01 Other
Events
On March 12, 2008, in connection with the
Companys press release issued on that same date, the Company scheduled an
investor conference call. A webcast
slide presentation covering corporate strategy and pipeline updates accompanied
the conference call commentary. A copy
of the webcast slide presentation is included as Exhibit 99.2 to this Form 8-K.
Item 9.01 Financial
Statements and Exhibits.
(d)
Exhibits
The
following exhibits are filed herewith:
99.1
Press
Release
dated March 12, 2008.
99.2 Contents of webcast slide presentation
dated March 12, 2008.
2
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized, in the City
of Portland, State of Oregon, on March 12, 2008.
|
AVI
BioPharma, Inc.
|
|
|
|
|
By:
|
/s/ ALAN
P. TIMMINS
|
|
|
|
|
|
Alan
P. Timmins
|
|
|
President and Chief Operating Officer
(Principal Operating Officer)
|
3
Exhibit Index
Exhibit
|
|
Description
|
|
|
|
Exhibit 99.1
|
|
Press
Release dated March 12, 2008.
|
|
|
|
Exhibit 99.2
|
|
Contents
of webcast slide presentation dated March 12, 2008.
|
4
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024